Setakat ini, katanya, Malaysia hanya meluluskan penggunaan vaksin Pfizer, Sinovac dan AstraZeneca sedangkan Pertubuhan Kesihatan Dunia (WHO) telah menyenaraikan Johnson & Johnson, Moderna dan Sinopharm untuk kegunaan kecemasan di seluruh dunia.- Hishammuddin Hussein

Sumber: https://www.malaysiakini.com/news/578764

The Current Status of MOU and Agreements Relating To NEXGRAM (0096)

https://klse.i3investor.com/blogs/mzm511/2021-06-14-story-h1566192317-The_Current_Status_of_MOU_and_Agreements_Relating_To_NEXGRAM_0096.jsp

MZM2511 A Pre-3QR 2021 Reporting: A Glance at the Revenue and Profit Growth of Nexgram for 2QR 2021
-----------------------
I am sorry. Some mistakes on the information in the blog article and corrected.

Among others, the incoming 3QR 2021 report should be announced at the end of this month instead of at the end of July 2021, In the condition that we are assuming the company didn't applied for the one month extension which was granted by the BURSA to certain company.

NicmannNg when the RI ex date fixed?
----------------------
Should be fixed after its approval in this incoming EGM (on 28 June 2021) .

JUST A THEORY TO SHARE

But as I looked at certain companies before, after the company approved the RI and setup the issue price for RI, the share price firstly will drop.

But near the date of the RI to be executed, the price will be markup higher than the issue price of the RI.

These scenario surely not be absolutely will happen to Kanger, but its has high chance or probabilty to follow suit.

AFTER ALL. TAYOR.

@BilisMasin. The issue price of the RI shares has been fixed @ 6 sen per share.

Thank you.
........

On behalf of the Board, UOB Kay Hian wishes to announce that the Board had on 26 April 2021 ("Price-Fixing Date") resolved to fix the issue price of the Rights Shares at RM0.06 per Rights Share ("Issue Price").

Source: https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3151261

Bukan untuk OKU_2020 ni. Untuk diri sendiri tengok saja. He He

A Pre-3QR 2021 Reporting: A Glance at the Revenue and Profit Growth of Nexgram for 2QR 2021

https://klse.i3investor.com/blogs/mzm511/2021-06-11-story-h1566077052-A_Pre_3QR_2021_Reporting_A_Glance_at_the_Revenue_and_Profit_Growth_of_N.jsp

Bukan tak sehh, itu Tok Sheikh (orang Arab).
Tak nak, kena sebut "tak seii"

@OKU-2020. Ambo nak tanya, berapa ketul saham Nexgram awak dapat beli time tu. He He

Aiyah. Sudah tunggu lama. 3 sen bila mahu dapat beli.
Soal kubur pun sudah keluar. He He

18KHarmoni Komen aku kena delete tadi, ko tulis artikel ko sendiri promote, kevavian apa kah ini
____________
Promote artikel tak salah, saya rasa. Yang salah ialah jika isi artikel mengandungi perkara-perkara yang tidak dibenarkan undang-undang termasuk Akta Sekuriti.

@Noobie123. I am sorry and oppoligize for the referred statement that is not true as stated. I already retracted my statement. Sorry.

@Nobie123. What are the plans for these units? Resale, rent out?

----------------------
The answer is here.

Pursuant to the Proposed Acquisition, the Group had entered into the SPA on 24 February 2021 to purchase the Subject Properties, which is currently under development and is expected to be completed within 54 months from the unconditional date of the SPA, in accordance with the terms and conditions of the SPA. The Group intends to sell the Subject Properties for capital gains.

Noobie123 Kanger is a Bamboo counter. Even the strategic outlook and approaches of Kanger never mention vaccine. It looked like vaccine not so important. It is just a bonus if can get.

----------------------------
HERE THE OFFICIAL ANNOUNCEMENT ABOUT THE PROGRESS OF PART OF PROJECTS THAT REPORTED IN MY ARTICLE. PLEASE BELIEVE IT. IT'S NOT A SCAM. HE HE

--------
GENERAL MEETINGS: Notice of Meeting

3. Description: PROPOSED DIVERSIFICATION OF THE EXISTING PRINCIPAL ACTIVITIES OF KANGER AND ITS SUBSIDIARIES TO INCLUDE CONSTRUCTION AND RELATED ACTIVITIES ("PROPOSED DIVERSIFICATION")

Shareholder’s Action: For Voting

2. Description PROPOSED ACQUISITION BY KANGER VENTURES SDN BHD (FORMERLY KNOWN AS KANGER DEVELOPMENT (M) SDN BHD), A WHOLLY-OWNED SUBSIDIARY OF KANGER, OF 126 UNITS OF PROPOSED SERVICED APARTMENTS LOCATED ON THE 30TH TO 45TH FLOORS OF TOWER A, ANTARA @ GENTING HIGHLANDS, SITED ON A PIECE OF FREEHOLD LAND HELD UNDER TITLE NO. GRN 45572 (FORMERLY HSD 18603), LOT 43031 (FORMERLY PT 23923), MUKIM AND DISTRICT OF BENTONG, PAHANG DARUL MAKMUR FROM THE DEVELOPER, NAMELY ASET KAYAMAS SDN BHD ("VENDOR") FOR A TOTAL PURCHASE CONSIDERATION OF RM142,870,000 TO BE SATISFIED ENTIRELY VIA CASH ("PROPOSED ACQUISITION")

Shareholder’s Action For Voting

Source: https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3165620

@Nobie123. I agree.

I noticed that all the revenue of the company for the last QR and this incoming QR just only derive from bamboo flooring and related goods. There are no other substantial source of revenue.

The construction jobs only to start this month and won't give any effect on their incoming QR.

Other project still in their form of mou or agreement.
Some seen like in the progressing state, some without any further news and some maybe has been lapsed.

Noobie123 MZM2511, So fast you forgot what you posted ah?

--------------------------------------
The information posted by me that referred by you was just to answer issue which was asked by our group member hlh1962. Actually, the information was an excerpt from the last QR report of Kanger.


MZM2511 @18KHarmoni. He He. Saja nak tolong beri pencerahan sikit kepada issue yang dibangkitkan saudara kita . Prospek bisnis semasa kan buuuluuuh. Vaksin tu BONUS.

-------------------
hlh1962 If next QR got revenue and profit then there is hope and not scam like Ikan bilis says. If still like last QR then something is quite wrong somewhere
08/06/2021 9:14 PM

@hlh1962. My information shared with others in the shares forum or written in my blog articles actually has been written carefully. Not to be categorised as an untrue information.

I also avoided to give a direct call/advice to buy or to sell any company shares. I don't have a legal licence to do such acts.

I'm just want to share the information. I'm obliged to say that I have an interest in the shares of this counter, Kanger (0017).

Thank you.

@Noobie123.
1. The company already involved in construction services.
2. In the process to acquire Properties business
3. In the process to acquire sales and trading construction material business
4. and of course for Covid-19 vaccine business,they just in the process of trying to secure the said business. It's true to say that the most critical aspect to get is the approval of Sinopharm vaccine in Malaysia by goverment/NPRA.

Please refer to this article: https://klse.i3investor.com/blogs/mzm511/2021-06-07-story-h1566103030-The_Currents_Status_of_MOUs_and_Agreements_Relating_To_KANGER_0170.jsp

@BilisMasin
The progress is here:

Report 1: The Sinopharm Covid-19 vaccine is in the process of being approved in Malaysia, including by the National Pharmaceutical Regulatory Agency (NPRA).

“We will ensure that we obtain the required approvals from relevant authorities before we commence distribution of the Sinopharm vaccines.

“Once approvals are obtained, the people of Sabah will be one of the early recipients of the Sinopharm vaccines,” Kuah said.

(Source: https://www.theedgemarkets.com/article/kanger-signs-mou-sabah-govt-procure-chinas-sinopharm-covid19-vaccines).

Report 2: Kanger International executive director Steven Kuah told reporters that, “the process of registering the Sinopharm vaccine (with NPRA) has started and we hope to receive some good news on its approval soon.”

(Source: https://www.freemalaysiatoday.com/category/nation/2021/05/27/sabah-signs-mou-with-private-firm-to-obtain-sinopharm-vaccine/ )

hlh1962. It's a possibility.

But as I looked at certain companies before, after the company approved the RI and setup the issue price for RI, the share price firstly will drop.
But near the date of the RI to be executed, the price will be markup higher than the issue price of the RI.
These scenario surely not be absolutely will happen to Kanger, but its has high chance or probabilty to follow suit.

AFTER ALL. TAYOR.

@hlh1962. I like to be open.
All the positive or negative information, I like it to be a true and factual based information, or if it's only a predictions or assumptions, it's predicted with some sort of supporting information.

For all. Dear friend, I'm sorry.

hlh1962. Furthermore,

1. On September 2020, Kanger planned to strengthen its bamboo products business. Kanger is on TARGET TO BECOME the world’s largest producer of bamboo products with the commencement of a new high-tech bamboo processing plant and R&D centre, which was developed in collaboration with the local government of Jingzhou, Hunan Province, China.

2. There are also some negative factors related to Kanger, among others;
(a) The profitability factor. Last QR reported big losess
(b) Proposed RI and warrants factor that can be ballooning their NOSH
(c) No sufficient cash to be used in exercising their proposal to acquire targeted companies. Instead, the company has to raised cash via RI and issuing new shares to the targeted companies.

hlh1962. There are only two agreements involving the prospect for Nexgram to secure jobs to service construction works. Other MOUs or agreements listed involved in other kind of proposal/projects.

1. The status for the Collaboration Agreement (CA) between Kanger Ventures and Multiple Novation which relating to a multiple constructions works (with the value of jobs if successfully secured all the listed the job @ RM495,855,518) is "No further announcement on the progress of this Collaboration Agreement yet by to date."
The CA maybe not yet finalized or has been lapsed. I'm not sure about it.

Source: https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3121737

2. Only the Collaboration Agreement between Vegetta Champion Sdn. Bhd. and Kanger Ventures Sdn. Bhd. a wholly owned subsidiary of Kanger, relating to a construction contract at Genting Highlands with contract value RM478 million has been finalised. The construction project contract under this collaboration agreement will start on June 2021 and its to be completed in 48 months.

Please refer to my blog article: https://klse.i3investor.com/blogs/mzm511/2021-06-07-story-h1566103030-The_Currents_Status_of_MOUs_and_Agreements_Relating_To_KANGER_0170.jsp

Diketepi dari MKN, menteri tegur cara k'jaan kendali vaksin, PPV

"Contoh kalau dunia boleh menerima penggunaan vaksin menerusi EUL (Senarai Kegunaan Darurat) dari negara asalnya dan WHO, kita harus menggunakannya untuk mendapatkan bekalan vaksin yang lebih beragam.

"Kita tak boleh hanya bergantung pada Covax dan NPRA untuk meluluskannya. Contoh hari ini ada vaksin lain seperti Sputnik V dan Sinopharm," tambahnya.

https://www.malaysiakini.com/news/578265

Diketepi dari MKN, menteri tegur cara k'jaan kendali vaksin, PPV

"Contoh kalau dunia boleh menerima penggunaan vaksin menerusi EUL (Senarai Kegunaan Darurat) dari negara asalnya dan WHO, kita harus menggunakannya untuk mendapatkan bekalan vaksin yang lebih beragam.

"Kita tak boleh hanya bergantung pada Covax dan NPRA untuk meluluskannya. Contoh hari ini ada vaksin lain seperti Sputnik V dan Sinopharm," tambahnya.

https://www.malaysiakini.com/news/578265

MCtrader not sure which vaccine, most likely china vaccine?
-----------------------

She however stated that Selangor is in the final stage to procure one of the vaccines approved by the National Pharmaceutical Regulatory Agency (NPRA), which is either Pfizer, Sinovac or AstraZeneca.

@BilisMasin. Setuju sepenuhnya dengan sebahagiannya, termasuk no. 1 dan 2.

Macam ni lah bagus. Baru gentleman.

But I want to differ for No. 3, 4 and 5. Just from my opinion and perspective only.

No. 3.
- There are may MOUs and Agreements signed and reported by the company.
- Some without any progress report.
- There is agreement that has been reported as a contract which is starting to commence and executed, with its dead line also reported.
- Some I think still in progressing state. Waiting for several requirements to be fulfilled before the MOUs or agreement can be executed, such as approvals from certain parties, internally or outside the company.

You can read here: https://klse.i3investor.com/blogs/mzm511/2021-06-07-story-h1566103030-...

No. 5.
- That's a kind of investments by the company.
- Some companies did it. Some can make profit but some suffered losses.

No.5.
- This kind of activities maybe played by insiders of the company or by sharks/operators or by the combination of the two parties.
- But its probably played by the sharks/operators alone who are not linked with insiders.
- If its involved sharks/operators without insiders play, WHAT CAN WE DO???

Kalau awak frust. Saya pun frust juga. COOL man.

Sabar @zzzzzzz. Sabar.

@18KHarmoni. Awak memang cerdik.
Sekadar pandai sebut Kanger con company.

Orang gila belakang rumah saya pun pandai sebut. He He

@18KHarmoni.
Which info is not true. Forward it here so all of us can see that the info is NOT TRUE.

-------------------
1. Article 1: https://klse.i3investor.com/blogs/httpsklsei3investorcomM/2021-05-29-story-h1565953920-Kanger_017_The_Bamboo_Flooring_And_Related_Products_Company_Is_Trying_H.jsp

REMARK: Let us read my conclusion.

Therefore, we are hoping that, sooner Kanger will be successful in securing their objective to be an approved Covid-19 vaccines distributor in Malaysia.

2. Article 2: https://klse.i3investor.com/blogs/httpsklsei3investorcomM/2021-06-02-story-h1566015706-Is_It_True_That_The_Process_of_Registering_The_Sinopharm_Vaccine_With_N.jsp

REMARK: Let us read my conclusion.

The Sinopharm / BIBP1 vaccine has been approved by WHO, whereas the Sinopharm / WIBP1 is still under its assessment process by WHO. Therefore, it’s better for Kanger to focus more on the currently approved vaccine by WHO, which is Sinopharm / BIBP1 for NPRA's approval. We, the investors of Kanger hope to receive some good news on its approval soon.

3. Article 3: https://klse.i3investor.com/blogs/mzm511/2021-06-07-story-h1566103030-The_Currents_Status_of_MOUs_and_Agreements_Relating_To_KANGER_0170.jsp

REMARKS: This article intended to report the current status of each MOUs and Agreements involving Kanger started from August 2020.

I wrote this article based on my research from www.bursamalaysia.com and information reported on the web. Any misreporting and emission of the information should not be my intention. All the information given is not for buy call or sell call purposes.

@18KHarmoni. Apa yang salah info nya.
Semua info saya ada rujukannya ada report dan linknya.
Saya berpandu kepada info saja.
Kenapa nak marah. Sekadar cari info dan cuba kongsi.
Percaya atau tidak fikir sendiri. TAYOR

Saya memang salesman. Bukan digaji oleh siapa-siapa.
Konsep saya, bila dah beli saham dalam sesuatu saham walaupun sedikit,
saya cuba "sale" kaunter tu jika mampu.

Cari maklumat dan ambil langkah untuk sebarkannya, termasuk buat artikel blog.
Alasan mestilah nak cover kaunter yang kita masuk.

Awak tengok sejarah saya dalam kaunter lain, termasuk Nexgram dan Bornoil.
Saya baru aktif dalam forum sejak tahun lepas sahaja.

Nampaknya betul-betul berpengaruh NPRA1985 sebelum ini.
Lebih baik awak bincang fasal Kanger saja.
Ada ke tak ada NPRA1985 di sini, bukan satu isu.
Teruskan saja usaha awak untuk kutuk Kanger.
Saya pun fikir elok juga kalau dapat harga yang lebih rendah nanti.
5.5 sen ke, 6 sen ke. He He

Nujum Pak Belalang memang pandai. Buat tekaan tanpa bukti pun.
Seperti selalu, naysayer tanpa bukti.

Rugi saya tak dapat bersama NPRA1985 sebelum ini di dalam kaunter ini memandangkan saya amat baharu di sini.

Daripada fikir fasal NPRA1985, lebih baik fikir fasal kaunter ni saja.

Dapatkan maklumat untuk kenal pasti potensi pelaburan di dalam kaunter ini perlu lebih diberi perhatian., tak kiralah sebagai "day trader" ke, spekulator ke atau investor untuk jangka panjang.

Bagi yang berperanan sebagai Naysayer pun ada gunanya, mereka dapat keluarkan isu untuk dijawab oleh pihak lain.

Di mana-mana kaunter pun ada pros dan cons.

Macquarie Bank to invest in Nice Capital Emas. I think due to the diversification of NICE’s existing core business to include exploration of minerals, gold mining (in Kelantan) and mining related business
-----------------
On 14 April 2021, NICE had entered into a subscription agreement with
Macquarie Bank for Macquarie Bank to subscribe for up to 124,000,000
NICE Shares.

On even date, NICE had also entered into a subscription agreement with
Mdm Heah to allot and issue 22,000,000 Placement Shares for a total
consideration of RM4,032,600 or at RM0.1833 per Placement Share.

@18KHarmoni. He He. Saja nak tolong beri pencerahan sikit kepada issue yang dibangkitkan saudara kita . Prospek bisnis semasa kan buuuluuuh. Vaksin tu BONUS.

-------------------
hlh1962 If next QR got revenue and profit then there is hope and not scam like Ikan bilis says. If still like last QR then something is quite wrong somewhere

Prospects for the financial period ending 31 March 2021 (“FPE 2021”)

The Group has identified the following main strategies to continue to grow its businesses:-

(a) Expansion into new bamboo concession and processing plant in Jingzhou, the PRC
which has commenced operations in current financial quarter.

(b) Expansion of the Group’s flooring products with the launching of new series of bamboo
flooring products.

(c) Enhancing the Group’s flooring products to focus more on ‘green’ strand woven
products.

(d) Expansion of the Group’s product portfolio to include bamboo furniture marketed under
the ‘KAR-ACE’ brand.

(e) Expansion into wood flooring products by promoting Classen’s products in the PRC
through the collaboration with Classen GmbH as the Group is the exclusive distributor
for Classen’s products in the PRC.

(f) Expansion of the Group’s presence by increasing the number of appointed dealers in
its sales network and number of sales and marketing channels, for both its own and
third party products.

(g) Identifying candidates to be the Group’s master agents/distributors in countries such
as Malaysia, Australia and New Zealand.

(h) Intensifying efforts in the adoption and building out of a comprehensive omni-channel
marketing strategy which is designed to cover all points of contact with existing and
potential new customers. The Group is also cooperating closely with its dealers in
implementing effective Online-to-Offline marketing and delivery channels. The online
platforms include JD.com, Alibaba’s Taobao and various mini-programs offered by
social media networks like WeChat.

Premised on the above, the Board is cautiously optimistic on the prospects of the Group for
FPE 2021.

@gohkimhock.
You can refer these blog articles to get some ideas about Kanger's efforts and chances to secure this vaccine business:

1. https://klse.i3investor.com/blogs/httpsklsei3investorcomM/2021-05-29-story-h1565953920-Kanger_017_The_Bamboo_Flooring_And_Related_Products_Company_Is_Trying_H.jsp

2. https://klse.i3investor.com/blogs/httpsklsei3investorcomM/2021-06-02-story-h1566015706-Is_It_True_That_The_Process_of_Registering_The_Sinopharm_Vaccine_With_N.jsp

@Noobie. He He. Ikan di air sudah nampak jantan betinanya.
Okay lah macam tu.
Terbukti awak masih ada sedikit faith dengan Kanger

@gohkimhock. You can have your own perception.
Your perception not surely true.
We don't know what will happen in the future.
There is a probability, therefore there stands a hope.

Nobody point a gun to make you believe it or not.

WHO lists additional COVID-19 vaccine for emergency use and issues interim policy recommendations

7 May 2021 News release Reading time: 3 min (917 words)

WHO today listed the Sinopharm COVID-19 vaccine for emergency use, giving the green light for this vaccine to be rolled out globally. The Sinopharm vaccine is produced by Beijing Bio-Institute of Biological Products Co Ltd, subsidiary of China National Biotec Group (CNBG).

WHO lists additional COVID-19 vaccine for emergency use and issues interim policy recommendations

7 May 2021 News release Reading time: 3 min (917 words)

WHO today listed the Sinopharm COVID-19 vaccine for emergency use, giving the green light for this vaccine to be rolled out globally. The Sinopharm vaccine is produced by Beijing Bio-Institute of Biological Products Co Ltd, subsidiary of China National Biotec Group (CNBG).

Procurement of the Covid-19 vaccines is a challenging task for the government.
Needs helps from private sector???

https://www.freemalaysiatoday.com/category/highlight/2021/06/07/ema-warns-against-heparin-for-covid-19-vaccine-clots/

The global capacity to manufacture vaccines remains limited: To cover 70 per cent of the global population, at least 11 billion doses are required. This need simply cannot be met by the manufacturers immediately.

High-income countries have acquired 77 per cent of Pfizer’s, 27 per cent of AstraZeneca’s and 18 per cent of Sinovac’s 2021 COVID-19 vaccine production capacity.

Estimates suggest that with an average of 60,433 doses administered daily, Indonesia would take over 10 years to vaccinate 75 per cent of its population.

The slow progress of COVID-19 vaccination in Indonesia can be put down to limited global vaccine supply, the unpreparedness of the national health system and vaccine hesitancy.

Aiyah....

@greedy44. There is only one project with MOU status from the list. The rest, it's an agreement or contract.

gohkimhock only Pharmaniaga and Duopharma are allowed by the Malaysian govt to deal with vaccine. The others(including ucrest and yongtai) are all just jumping on the bandwagon without proper license and knowledge. You can't even make simple medicine, wanna deal with vaccine?
-------------------------

1. Perjanjian sebagai SOLE DISTRIBUTOR yang dilantik untuk 3 tahun oleh Sinopharm dah ada - SETTLE

Sumber: https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3092107

2. MOU untuk wakil distributor bagi pihak Kanger dah ada iaitu Zuellig Pharma - SETTLE

Sumber:
1. https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3154098
2. https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3137884

Nota: Kanger will collaborate with ZP to facilitate the import, warehousing, and
distribution of Covid-19 vaccines in Malaysia. Kanger will receive 10,000 doses of a Covid-19 vaccine developed by state-owned China National Pharmaceutical Group Corp (Sinopharm) for trial purposes. The first batch of vaccines is expected to arrive in Malaysia on May 2021).


3. MOU untuk saluran jualan vaksin ke kilinik swasta di Malaysia dah ada iaitu KSport - SETTLE

Sumber:

1. https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3154097
2. https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3137884

SEKARANG TUNGGU UNTUK PROSES APPROVAL OLEH KERAJAAN DAN NPRA SAHAJA.

Artikel blog. Sapa-sapa nak tahu fasal perkembangan MOU dan agreement yang dibuat oleh Kanger boleh rujuk sini.

"The Currents Status of MOUs and Agreements Relating To KANGER (0170)"


https://klse.i3investor.com/blogs/mzm511/2021-06-07-story-h1566103030-The_Currents_Status_of_MOUs_and_Agreements_Relating_To_KANGER_0170.jsp